Compare Stocks: BYSI, BNR, CBUS, and INO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$14.23 +5.3%	$10.14	$6.79 ▼ $41.72	$149.72M	1.38	50,942 shs	24,500 shs
BYSI BeyondSpring	$0.75 +5.8%	$0.89	$0.57 ▼ $2.44	$30.83M	0.06	96,634 shs	45,280 shs
CBUS Cibus	$1.61 -1.2%	$1.76	$1.09 ▼ $4.19	$123.05M	1.59	99,607 shs	139,149 shs
INO Inovio Pharmaceuticals	$1.24 +2.5%	$1.10	$0.56 ▼ $2.72	$128.21M	1.63	3.16 million shs	2.89 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	0.00%	+15.88%	+53.84%	+96.28%	+72.07%
BYSI BeyondSpring	0.00%	-1.86%	+4.12%	-53.43%	-58.11%
CBUS Cibus	0.00%	+2.55%	-5.29%	+18.38%	+21.05%
INO Inovio Pharmaceuticals	0.00%	-0.80%	+2.48%	+11.21%	-43.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$14.23 +5.3%	$10.14	$6.79 ▼ $41.72	$149.72M	1.38	50,942 shs	24,500 shs
BYSI BeyondSpring	$0.75 +5.8%	$0.89	$0.57 ▼ $2.44	$30.83M	0.06	96,634 shs	45,280 shs
CBUS Cibus	$1.61 -1.2%	$1.76	$1.09 ▼ $4.19	$123.05M	1.59	99,607 shs	139,149 shs
INO Inovio Pharmaceuticals	$1.24 +2.5%	$1.10	$0.56 ▼ $2.72	$128.21M	1.63	3.16 million shs	2.89 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	0.00%	+15.88%	+53.84%	+96.28%	+72.07%
BYSI BeyondSpring	0.00%	-1.86%	+4.12%	-53.43%	-58.11%
CBUS Cibus	0.00%	+2.55%	-5.29%	+18.38%	+21.05%
INO Inovio Pharmaceuticals	0.00%	-0.80%	+2.48%	+11.21%	-43.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
BYSI BeyondSpring	1.00	Sell	N/A	N/A
CBUS Cibus	2.00	Hold	$9.00	459.01% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	155.38% Upside

Current Analyst Ratings Breakdown

Latest BYSI, BNR, CBUS, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	1.94	N/A	N/A	$7.28 per share	1.95
BYSI BeyondSpring	$1.75M	17.62	$0.11 per share	6.60	($0.59) per share	-1.27
CBUS Cibus	$3.64M	33.81	N/A	N/A	$0.40 per share	4.03
INO Inovio Pharmaceuticals	$60K	2,136.93	N/A	N/A	$0.36 per share	3.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
BYSI BeyondSpring	-$1.01M	-$0.12	N/A	N/A	N/A	N/A	N/A	-28.88%	11/12/2026 (Estimated)
CBUS Cibus	-$127.08M	-$1.65	N/A	N/A	N/A	-2,258.89%	-287.03%	-27.99%	11/12/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)

Latest BYSI, BNR, CBUS, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/13/2026	Q2 2026	CBUS Cibus	-$0.19	-$0.29	-$0.10	-$0.29	$1.70 million	$0.99 million
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CBUS Cibus	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
BYSI BeyondSpring	N/A	0.70	0.70
CBUS Cibus	N/A	1.62	1.62
INO Inovio Pharmaceuticals	N/A	1.00	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
BYSI BeyondSpring	40.29%
CBUS Cibus	33.81%
INO Inovio Pharmaceuticals	26.79%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
BYSI BeyondSpring	29.31%
CBUS Cibus	29.91%
INO Inovio Pharmaceuticals	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
BYSI BeyondSpring	44	41.12 million	29.07 million	Optionable
CBUS Cibus	118	76.43 million	53.57 million	Optionable
INO Inovio Pharmaceuticals	112	103.40 million	101.64 million	Optionable

BYSI, BNR, CBUS, and INO Headlines

Recent News About These Companies

Inovio Pharmaceuticals stock gains as price crosses 200-day moving average

September 19 at 2:23 PM | ad-hoc-news.deA

Inovio Pharmaceuticals (NASDAQ:INO) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

September 19 at 1:41 AM | americanbankingnews.com

Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above 200 Day Moving Average - Here's Why

September 19 at 1:39 AM | marketbeat.com

Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view

September 18 at 12:29 PM | ad-hoc-news.deA

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

September 14, 2026 | finance.yahoo.com

Bet on 4 Top-Ranked Stocks With Rising P/E

September 14, 2026 | zacks.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $3.17 Average PT from Analysts

September 12, 2026 | americanbankingnews.com

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

September 11, 2026 | seekingalpha.com

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

September 11, 2026 | marketbeat.com

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

September 10, 2026 | finance.yahoo.com

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

September 10, 2026 | marketbeat.com

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9, 2026 | seekingalpha.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Bet on 5 Top-Ranked Stocks With Rising P/E

September 3, 2026 | zacks.com

INOVIO to Participate in Upcoming Investor Conferences

September 1, 2026 | finance.yahoo.com

INOVIO to Participate in Upcoming Investor Conferences

September 1, 2026 | prnewswire.com

Inovio Pharmaceuticals (NASDAQ:INO) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened

September 1, 2026 | marketbeat.com

Inovio: The Final Countdown To A Binary FDA Decision

August 25, 2026 | seekingalpha.com

Inovio (INO) Q2 2026 Earnings Call Transcript

August 13, 2026 | theglobeandmail.com

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 13, 2026 | finanznachrichten.de

Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

August 13, 2026 | app.moby.coA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, BNR, CBUS, and INO Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$14.23 +0.71 (+5.25%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.90 +0.67 (+4.74%)

As of 09/18/2026 07:30 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

BeyondSpring NASDAQ:BYSI

$0.75 +0.04 (+5.78%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.75 0.00 (-0.11%)

As of 09/18/2026 06:48 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Cibus NASDAQ:CBUS

$1.61 -0.02 (-1.23%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.60 -0.01 (-0.31%)

As of 09/18/2026 07:30 PM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.24 +0.03 (+2.48%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.23 -0.01 (-0.89%)

As of 09/18/2026 07:55 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BYSI, BNR, CBUS, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BYSI, BNR, CBUS, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BYSI, BNR, CBUS, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, BNR, CBUS, and INO Company Descriptions

Burning Rock Biotech NASDAQ:BNR

BeyondSpring NASDAQ:BYSI

Cibus NASDAQ:CBUS

Inovio Pharmaceuticals NASDAQ:INO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BYSI, BNR, CBUS, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BYSI, BNR, CBUS, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BYSI, BNR, CBUS, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, BNR, CBUS, and INO Company Descriptions

Burning Rock Biotech NASDAQ:BNR

BeyondSpring NASDAQ:BYSI

Cibus NASDAQ:CBUS

Inovio Pharmaceuticals NASDAQ:INO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools